Sage Therapeutics
215 First Street
Cambridge
MA
02142
United States
Tel: 617-299-8380
Website: https://www.sagerx.com/
About Sage Therapeutics
Welcome To The Workplace With A Difference
Our vision is to fearlessly lead the way to create a world with better brain health – a vision we can only achieve with the help of our amazing team of highly knowledgeable, deeply passionate individuals.
At Sage, we believe that life is more than just a destination. We’re concerned with the journey, and we care deeply about everyone contributing to and benefiting from our own company journey. This means helping people discover the right path for them and carefully guiding colleagues along the way.
Stock Symbol:
SAGE
Fly-through video of our Cambridge Office. Feel what it's like to be on site.
404 articles about Sage Therapeutics
-
SAGE Therapeutics Crashes Hard as Lead Epilepsy Drug Flunks Phase III Test
9/13/2017
-
Does SAGE Therapeutics' Failure Predict Its Future Results?
9/13/2017
-
SAGE Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9/7/2017
-
SAGE Therapeutics Announces Second Quarter 2017 Financial Results And Provides Pipeline Update
8/4/2017
-
SAGE Therapeutics To Report Second Quarter 2017 Financial Results On Thursday, August 3, 2017
7/21/2017
-
SAGE Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
7/11/2017
-
SAGE Therapeutics Announces The Lancet Publishes Positive Phase II Brexanolone (SAGE-547) Clinical Data In Severe Postpartum Depression
6/13/2017
-
SAGE Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6/5/2017
-
SAGE Therapeutics Receives Fast Track Designation For SAGE-217 For The Treatment Of Major Depressive Disorder
5/18/2017
-
SAGE Therapeutics Announces First Quarter 2017 Financial Results And Provides Pipeline Update
5/10/2017
-
SAGE Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5/5/2017
-
SAGE Therapeutics Announces Initiation Of Phase I Development And First Dosing Of SAGE-718
4/27/2017
-
SAGE Therapeutics To Report First Quarter 2017 Financial Results On Tuesday, May 9, 2017
4/26/2017
-
SAGE Therapeutics Appoints Michael Cloonan As Chief Business Officer And Expands Executive Team
4/24/2017
-
SAGE Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
4/6/2017
-
SAGE Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3/3/2017
-
SAGE Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2/23/2017
-
SAGE Therapeutics Takes Investors On A Wild Ride As CEO Talks Up Brain Drugs
2/22/2017
-
SAGE Therapeutics To Report Fourth Quarter And Full Year 2016 Financial Results On Thursday, February 23, 2017
2/17/2017
-
SAGE Therapeutics Boss Gets Overenthusiastic About Drug, Walks Back Discussion of M&A Activity
2/17/2017